Lantern Pharma Inc. (NASDAQ: LTRN) announced development plans for its withZeta.ai artificial intelligence platform, including two new feature sets planned for release in the coming year.

The company outlined plans for ZetaSwarm, described as an autonomous multi-agent swarm intelligence layer, and ZetaOmics, a computational biology and multi-omic analytics toolkit. The additions are intended to expand the platform's current foundation of 34 bioinformatics, chemoinformatic, and clinical research tools.

ZetaSwarm is designed as a coordinated network of specialist AI agents operating in parallel on scientific problems. The system would use a coordinator-and-reviewer architecture across 15 distinct agent configurations spanning medicinal chemistry, clinical trial strategy, clinical oncology, biomarkers, and general scientific reasoning.

ZetaOmics is planned as both a standalone bioinformatics toolkit and a computational layer for ZetaSwarm agents. The toolkit would provide real-time multiomic biomarker and drug response analytics using curated datasets including TCGA, GTEx, TARGET, NCBI GEO, and NCI-60.

The company also outlined enterprise-grade platform capabilities including workspace and organization-level accounts, comprehensive audit trails, and private knowledge bases for institutional deployment.

"With this roadmap, a researcher can ask withZeta.ai a single complex question — evaluate a compound, profile an indication, design a trial cohort — and have a coordinated team of specialist agents parse it, run real computational analyses on real biomarker data, and converge on a synthesized, auditable answer in one session," said Panna Sharma, President and CEO of Lantern Pharma.

The withZeta.ai platform is currently commercially available with a subscription payment model. The company noted this represents a non-dilutive revenue stream in a market for AI-focused drug development tools valued at nearly $15 billion.

Information is based on a company press release.